Drugs / GSK2132231A
GSK2132231A
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00942162 | Aug 2009 → Jun 2012 | melanoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00849875 | May 2009 → Nov 2014 | melanoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00896480 | May 2009 → Nov 2014 | melanoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00796445 | Dec 2008 → Jan 2016 | melanoma | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 2132231A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00796445 ↗ |
| Known as | MAGE-A3 cancer immunotherapeutic | “Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine” PMID 29177094 ↗ Nov 2017 |
| Known as | MAGE-A3 immunotherapeutic | “recombinant MAGE-A3 antigen combined with AS15 immunostimulant (MAGE-A3 immunotherapeutic)” PMID 29177094 ↗ Nov 2017 |
| Route | Intramuscular | “Study products were administered as intramuscular (IM) injections” NCT00796445 ↗ |